Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417108 | 1.00 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL3856709 | 1.00 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL29881540 | 1.00 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| Ammonia Solution, Strong SCHEMBL17473691 | 0.98 | OPRM1 (0.48) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL4708786 | 0.93 | OPRM1 (0.54) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL8995127 | 0.91 | OPRM1 (0.52) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL21307765 | 0.89 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| Octodrine SCHEMBL8343075 | 0.88 | OPRM1 (0.40) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL18283422 | 0.85 | OPRM1 (0.41) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL5787559 | 0.85 | OPRM1 (0.41) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112266356-A | Asymmetric synthesis method of (S) -chloroquine phosphate | 陈旭桓 | 2021-01-26 | — | — | CN | claimed |
| CN-114591251-B | Chiral aminoquinazoline compound, and preparation method and application thereof | 华南理工大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-111803501-B | Use of chiral chloroquine hydroxychloroquine for reducing cardiotoxicity | 南方科技大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-114591251-A | Chiral aminoquinazoline compound and preparation method and application thereof | 华南理工大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-112266356-A | Asymmetric synthesis method of (S) -chloroquine phosphate | 陈旭桓 | 2021-01-26 | — | — | CN | disclosed |
| CN-112266356-A | Asymmetric synthesis method of (S) -chloroquine phosphate | 陈旭桓 | 2021-01-26 | — | — | CN | disclosed |
| CN-111803501-A | Application of chiral chloroquine hydroxychloroquine or salt thereof as anti-coronavirus drug target 3CL hydrolase inhibitor for reducing cardiotoxicity | 南方科技大学 | 2020-10-23 | — | — | CN | disclosed |
| EP-1687275-A4 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | AGT SCIENCE LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| CN-1882546-A | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | MERCK & CO INC (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1687275-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | Merck & Co., Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051915-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | PER2, CNR2, OPRD1 | OPRM1 53/4885PLA2G1B 2144/4885PLA2G2A 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.